The 20 Best Juvenile Myelomonocytic Leukemia (JMML) Doctors Near Me in Washington, DC

Reuven Schore, MD, is a pediatric oncologist and a member of the Leukemia/Lymphoma Program at Children's National Hospital. Dr. Schore is an associate professor, pediatrics at George Washington University School of Medicine. Dr. Schore is the vice chair for a Children's Oncology Group study investigating intravenous treatments for patients with high-risk acute lymphoblastic leukemia (ALL). Dr. Schore is rated as an Advanced provider by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), and Febrile Neutropenia. Dr. Schore is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2006 and Pediatrics: American Board Of Pediatrics, 2003.

Anant Vatsayan, MBBS, is a blood and marrow transplant/cellular therapy attending at Children’s National Hospital. He is an assistant professor of pediatrics at the George Washington School of Medicine and Health Sciences, the cellular therapy laboratory medical director, and the pediatric BMT fellowship director for the joint NCI/Children’s National Hospital BMT Fellowship Program. He is a board-certified pediatric hematologist/oncologist. Prior to joining Children’s National, Dr. Vatsayan completed a two-year fellowship in cellular therapy/blood and marrow transplantation (BMT) at Memorial Sloan Kettering Center, New York. He did his pediatric hematology/oncology fellowship at Rainbow Babies and Children’s Hospital, Case Western Reserve University, Cleveland, Ohio. His research interests include BMT/cellular therapies for pediatric high-risk hematologic malignancies. He is the clinical lead for the Chimeric Antigen Receptor T (CAR-T) therapy program at Children’s National. His other interests include novel transplantation techniques like TCR alpha/beta T cell depleted BMT, graft versus host disease and BMT for high-risk inherited bone marrow failure syndromes, like Fanconi anemia. Dr. Vatsayan is rated as an Experienced provider by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). His clinical expertise encompasses Non-Langerhans-Cell Histiocytosis, Hemophagocytic Lymphohistiocytosis, Acquired Amegakaryocytic Thrombocytopenia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant. Dr. Vatsayan is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2017 and Pediatrics: American Board Of Pediatrics, 2013.

David Jacobsohn, MD, ScM, MBA, is the division chief of the Blood and Marrow Transplantation Program at Children’s National Hospital and full professor of Pediatrics at the George Washington University. He leads a program of upwards of 70 pediatric transplants per year. The program performs transplants in patients with malignant and non-malignant conditions, and has expertise with all stem cell sources including haplo-identical transplants. His expertise is in graft-versus-host disease (GvHD) clinical trials: reducing incidence of GvHD as well as novel therapies for GvHD. He has more than 10 years of experience in clinical research in pediatric GvHD. His work has included the study of novel drugs for chronic GvHD, classification criteria for chronic GvHD, and risk factor stratification in pediatric chronic GvHD. He is active in the BMT community at a national level. Examples of some current and prior roles include head of the GVHD committee for the Pediatric Blood and Marrow Transplant Consortium, member-at-large of the that Consortium, member of the Children’s Oncology Group Stem Cell Transplant Committee, member of the Clinical Trials Network State of the Science Pediatric Advisory Group. Dr. Jacobsohn has been instrumental in growing the capabilities of the Blood and Marrow Transplant Program. For example, for the last five years the program is one of the few pediatric programs performing alpha/beta T cell depletion for haploidentical transplants. This novel method for GVHD prevention has significantly improved the outcome of haploidentical BMT at Children’s National. Additionally, he has been involved with the deployment of gene therapy for hemoglobinopathies. He successfully led Children’s National to become the first program in the country to collect stem cells for a commercial sickle cell gene therapy treatment. Dr. Jacobsohn is rated as an Experienced provider by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Hemoglobinopathy, Anemia, Sickle Cell Disease, and Bone Marrow Transplant. Dr. Jacobsohn is board certified in Pediatric Hematology-Oncology: American Board Of Pediatrics, 2002 and Pediatrics: American Board Of Pediatrics, 1999.

Blachy Davila is a Hematologist and an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Davila is rated as an Experienced provider by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Severe Combined Immunodeficiency (SCID), Hemophagocytic Lymphohistiocytosis, Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

Jeffrey Toretsky is a Hematologist and an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Toretsky is rated as an Experienced provider by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration.